Ven­ture fund starts an­ti­body biotech in Delaware; CRO changes pri­vate eq­ui­ty hands

On Mon­day, a Lux­em­bourg ven­ture fund an­nounced their in­vest­ment of an undis­closed amount in­to es­tab­lish­ing a mon­o­clon­al an­ti­body-fo­cused biotech. The biotech has no web­site, but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER